• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Level of evidence for therapeutic drug monitoring of ceftriaxone].

作者信息

Dailly Eric, Verdier Marie-Clémence, Deslandes Guillaume, Bouquié Régis, Tribut Olivier, Bentué-Ferrer Danièle

机构信息

Service de Pharmacologie Clinique, CHU de Nantes, Nantes, France.

出版信息

Therapie. 2012 Mar-Apr;67(2):145-9. doi: 10.2515/therapie/2012018. Epub 2012 Aug 2.

DOI:10.2515/therapie/2012018
PMID:22850101
Abstract

Ceftriaxone is a third generation cephalosporin with an original pharmacokinetics based on a long elimination half-life among cephalosporins, a high protein binding and a dual renal and biliary elimination. Also the pharmacokinetic parameters of ceftriaxone are highly variable in clinical situations such as severe renal insufficiency, liver and renal insufficiency, the elderly, the neonates less than 1 week of age and critically ill patients. In these clinical situations associated or not with high minimal inhibitory concentration (MIC) level, the relationship concentration-clinical outcome based on the ratio between trough plasma concentration and MIC can allow a dose adjustment. Consequently, therapeutic drug monitoring (TDM) of ceftriaxone could be possibly useful in these situations, whereas the necessity of TDM has still to be demonstrated to monitor toxicity.

摘要

相似文献

1
[Level of evidence for therapeutic drug monitoring of ceftriaxone].
Therapie. 2012 Mar-Apr;67(2):145-9. doi: 10.2515/therapie/2012018. Epub 2012 Aug 2.
2
[Level of evidence for therapeutic drug monitoring of aminoglycosides].[氨基糖苷类药物治疗药物监测的证据级别]
Therapie. 2011 Jan-Feb;66(1):39-44. doi: 10.2515/therapie/2011001. Epub 2011 Apr 7.
3
In vitro activity, pharmacokinetics, clinical efficacy, safety and pharmacoeconomics of ceftriaxone compared with third and fourth generation cephalosporins: review.头孢曲松与第三代和第四代头孢菌素相比的体外活性、药代动力学、临床疗效、安全性及药物经济学:综述
J Chemother. 2005 Feb;17(1):3-24.
4
[Level of evidence for therapeutic drug monitoring of vancomycin].[万古霉素治疗药物监测的证据级别]
Therapie. 2011 Jan-Feb;66(1):29-37. doi: 10.2515/therapie/2011005. Epub 2011 Apr 7.
5
Pharmacokinetics and pharmacodynamic target attainment of ceftriaxone in adult severely ill sub-Saharan African patients: a population pharmacokinetic modelling study.成人重症撒哈拉以南非洲患者头孢曲松的药代动力学和药效学目标达成情况:一项群体药代动力学模型研究。
J Antimicrob Chemother. 2018 Jun 1;73(6):1620-1629. doi: 10.1093/jac/dky071.
6
Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept.危重症患者β-内酰胺类药物的治疗药物监测:概念验证。
Int J Antimicrob Agents. 2010 Oct;36(4):332-9. doi: 10.1016/j.ijantimicag.2010.06.008. Epub 2010 Aug 3.
7
Clinical pharmacokinetics of ceftriaxone.头孢曲松的临床药代动力学。
Clin Pharmacokinet. 1989 Oct;17(4):223-35. doi: 10.2165/00003088-198917040-00002.
8
[Therapeutic drug monitoring of stiripentol].[司替戊醇的治疗药物监测]
Therapie. 2012 Mar-Apr;67(2):157-60. doi: 10.2515/therapie/2012014. Epub 2012 Aug 2.
9
Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model.头孢曲松在肝肾功能不全患者中的药代动力学及其与生理非线性蛋白结合模型的相关性
Am J Med. 1984 Oct 19;77(4C):26-32.
10
β-Lactam therapeutic drug monitoring in the critically ill: optimising drug exposure in patients with fluctuating renal function and hypoalbuminaemia.β-内酰胺类药物治疗药物监测在危重症患者中的应用:优化肾功能波动和低白蛋白血症患者的药物暴露。
Int J Antimicrob Agents. 2013 Feb;41(2):162-6. doi: 10.1016/j.ijantimicag.2012.10.002. Epub 2012 Nov 13.